Sign inJoin waitlistJoin the waitlist

Juan Alderuccio

Clinical Research Lead · University of Miami/Jackson Health System

Credentials: · · · ·

History

University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

Hematology and Medical Oncology
Jackson Memorial Hospital
2016–2019
New York Metropolitan Hospital
2013–2016
Instituto Universitario de las Ciencias de la Salud
1999–2003

Research

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology · 2021 · 394 citations
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Blood · 2021 · 94 citations
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
Journal of Clinical Oncology · 2018 · First of 12 authors · 71 citations

Izidore Lossos
55 papers
BK
Brad Kahl
14 papers
Narendranath Epperla
11 papers
Paolo Caimi
11 papers
Russ Kuker
11 papers
Craig Moskowitz
10 papers
Thomas Habermann
10 papers
Alvaro Alencar
9 papers
JF
Jorge Florindez
9 papers
Brian Hess
8 papers
BL
Brian Link
8 papers
Peter Martin
8 papers

Clinical trials

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Principal investigator · Recruiting · Phase 2
University of Miami
2026–2031
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Principal investigator · Recruiting · Phase 1
Juan P. Alderuccio, MD
2025–2030
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Principal investigator · Recruiting · Phase 2
Juan P. Alderuccio, MD
2022–2030
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Site PI · Recruiting · Phase 2
University of Miami
2025–2030